Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions

Cancer Treatment Reviews

Volumn 34, Issue 7, 2008, Pages 629-639

  Coleman, Robert ^a   Brown, Janet ^b   Terpos, Evangelos ^c   Lipton, Allan ^d   Smith, Matthew R ^e   Cook, Richard ^f   Major, Pierre ^g  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UNIVERSITY OF WATERLOO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone alkaline phosphatase; Bone sialoprotein; C telopeptide of type I collagen; N telopeptide of type I collagen; Osteoprotegerin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN DERIVATIVE; DEOXYPYRIDINOLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PYRIDINOLINE; PYRIDINOLINE CROSSLINKED CARBOXY TERMINAL TELOPEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METABOLISM; BONE METASTASIS; BONE REMODELING; CLINICAL TRIAL; DRUG RESPONSE; ENZYME IMMUNOASSAY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MEDLINE; OSSIFICATION; OSTEOLYSIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; REVIEW; SOLID TUMOR;

ADULT; AGED; ALKALINE PHOSPHATASE; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOCALCIN; OSTEOPROTEGERIN; PROCOLLAGEN; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 53649083433     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.05.001     Document Type: Review

References (90)

1. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
2. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
3. Watts N.B. Clinical utility of biochemical markers of bone remodeling. Clin Chem 45 (1999) 1359-1368
4. Krane S.M. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med 201 (2005) 841-843
5. de Baat P., Heijboer M.P., and de Baat C. [Development, physiology, and cell activity of bone]. Ned Tijdschr Tandheelkd 112 (2005) 258-263
6. Seeman E., and Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354 (2006) 2250-2261
7. Fohr B., Dunstan C.R., and Seibel M.J. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88 (2003) 5059-5075
8. Tanaka S., Miyazaki T., Fukuda A., et al. Molecular mechanism of the life and death of the osteoclast. Ann N Y Acad Sci 1068 (2006) 180-186
9. Take I., Takahash N., and Kurihara S. [Molecules which are involved in osteoclastic bone resorption: from the aspect of targets of treatment for osteoporosis]. Clin Calcium 15 (2005) 741-746
10. Katagiri T., and Fukuda T. [Molecular mechanisms of bone formation and bone-forming factors]. Clin Calcium 15 (2005) 17-22
11. Thomsen J.S., Ebbesen E.N., and Mosekilde L. Predicting human vertebral bone strength by vertebral static histomorphometry. Bone 30 (2002) 502-508
12. Tothill P., and Hannan W.J. Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry. Osteoporos Int 18 (2007) 1515-1523
13. University of Washington Department of Laboratory Medicine Immunology Division. Bone alkaline phosphatase (BAP) in serum. Available at: ; 2008 [accessed 21.04.08].
14. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., and Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858-864
15. Kanakis I., Nikolaou M., Pectasides D., Kiamouris C., and Karamanos N.K. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal 34 (2004) 827-832
16. Heuck C., and Wolthers O.D. A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover. J Endocrinol 159 (1998) 127-131
17. Caillot-Augusseau A., Lafage-Proust M.H., Soler C., Pernod J., Dubois F., and Alexandre C. Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95). Clin Chem 44 (1998) 578-585
18. Puistola U., Risteli L., Kauppila A., Knip M., and Risteli J. Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J Clin Endocrinol Metab 77 (1993) 178-182
19. Bauer D.C., Garnero P., Hochberg M.C., et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21 (2006) 292-299
20. Nguyen T.V., Meier C., Center J.R., Eisman J.A., and Seibel M.J. Bone turnover in elderly men: relationships to change in bone mineral density. BMC Musculoskelet Disord 8 (2007) 13
21. Balcerzak M., Hamade E., Zhang L., et al. The roles of annexins and alkaline phosphatase in mineralization process. Acta Biochim Pol 50 (2003) 1019-1038
22. Ivaska K.K., Kakonen S.-M., Gerdhem P., Obrant K.J., Pettersson K., and Vaananen H.K. Urinary osteocalcin as a marker of bone metabolism. Clin Chem 51 (2005) 618-628
23. Calvo M.S., Eyre D.R., and Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17 (1996) 333-368
24. Terpos E., Politou M., and Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 19 (2005) 125-142
25. Thurairaja R., Iles R.K., Jefferson K., McFarlane J.P., and Persad R.A. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76 (2006) 67-71
26. Brasso K., Christensen I.J., Johansen J.S., et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66 (2006) 503-513
27. Coleman R.E. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94 (2002) 2521-2533
28. Pecherstorfer M., Seibel M.J., Woitge H.W., et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90 (1997) 3743-3750
29. Hou M.F., Tsai L.Y., Tsai S.M., et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 15 (1999) 452-460
30. Souberbielle J.-C. Utilisation des marqueurs du remodelage osseux dans l'osteoporose. J Inf Biomed [in French] (2004) 9-11
31. Osteomark NTX accurate answers for osteoporosis patient management: urine ELISA, serum ELISA. Available at: ; 2008 [accessed 21.04.08].
32. Pectasides D., Farmakis D., Nikolaou M., et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 37 (2005) 171-176
33. Shimozuma K., Sonoo H., Fukunaga M., Ichihara K., Aoyama T., and Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29 (1999) 16-22
34. Jakob C., Zavrski I., Heider U., et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 9 (2003) 3047-3051
35. Politou M., Terpos E., Nadal E., Crawley C., Apperley J.F., and Rahemtulla A. Prolonged effect of reduced intensity conditioning (RIC) allogeneic transplantation for multiple myeloma on biochemical markers of bone remodelling and osteoclast function: report of a case. Haema 7 (2004) 87-91
36. Morena M., Terrier N., Jaussent I., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17 (2006) 262-270
37. Guang-da X., Hui-ling S., Zhi-song C., and Lin-shuang Z. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90 (2005) 5765-5768
38. Ju H.-S., Leung S., Brown B., et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 43 (1997) 1570-1576
39. Demers L.M., Costa L., Chinchilli V.M., Gaydos L., Curley E., and Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41 (1995) 1489-1494
40. Vinholes J., Guo C.Y., Purohit O.P., Eastell R., and Coleman R.E. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73 (1996) 1089-1095
41. Leeming D.J., Koizumi M., Byrjalsen I., Li B., Qvist P., and Tanko L.B. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15 (2006) 32-38
42. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
43. Sassi M.L., Eriksen H., Risteli L., et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26 (2000) 367-373
44. Halleen J.M., Ylipahkala H., Alatalo S.L., et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71 (2002) 20-25
45. Terpos E., de la Fuente J., Szydlo R., et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106 (2003) 455-457
46. Alatalo S.L., Ivaska K.K., Waguespack S.G., Econs M.J., Vaananen H.K., and Halleen J.M. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50 (2004) 883-890
47. Raynal C., Delmas P.D., and Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137 (1996) 2347-2354
48. Valverde P., Tu Q., and Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 20 (2005) 1669-1679
49. Nagata T., Bellows C.G., Kasugai S., Butler W.T., and Sodek J. Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem J 274 (1991) 513-520
50. Ek-Rylander B., Flores M., Wendel M., Heinegard D., and Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 269 (1994) 14853-14856
51. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., and Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7 (2001) 4060-4066
52. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783-791
53. Woitge H.W., Pecherstorfer M., Horn E., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84 (2001) 344-351
54. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
55. Dovio A., Data V., and Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?. J Endocrinol Invest 28 Suppl. (2005) 14-22
56. Rogers A., and Eastell R. Review: circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 (2005) 6323-6331
57. Mountzios G., Dimopoulos M.A., Bamias A., et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46 (2007) 221-229
58. Aoshima H., Kushida K., Takahashi M., et al. Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22 (1998) 73-78
59. Pedersen B.J., Schlemmer A., Rosenquist C., Hassager C., and Christiansen C. Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Osteoporos Int 5 (1995) 472-477
60. Shaarawy M., and Hasan M. Serum bone sialoprotein: a marker of bone resorption in postmenopausal osteoporosis. Scand J Clin Lab Invest 61 (2001) 513-521
61. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., and Christiansen C. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
62. Wolthers O.D., Heuck C., and Heickendorff L. Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 47 (2001) 1721-1722
63. Kleerekoper M. Use of bone markers in the management of women with low bone density. Am Soc Reprod Med Menopausal Med 10 (2002) 5-7
64. Fall P.M., Kennedy D., Smith J.A., Seibel M.J., and Raisz L.G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 11 (2000) 481-485
65. Vinholes J.J., Purohit O.P., Abbey M.E., Eastell R., and Coleman R.E. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8 (1997) 1243-1250
66. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
67. Lipton A., Cook R.J., Major P., Smith M.R., and Coleman R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12 (2007) 1035-1043
68. Hirsh V., Major P.P., Lipton A., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3 (2008) 228-236
69. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008 [Epub ahead of print].
70. Ali S.M., Demers L.M., Leitzel K., et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15 (2004) 455-459
71. Abildgaard N., Brixen K., Kristensen J.E., Eriksen E.F., Nielsen J.L., and Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120 (2003) 235-242
72. Menssen H.D., Sakalova A., Fontana A., et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20 (2002) 2353-2359
73. Holen I., Hannon R.A., Ellis S.P., Coleman R.E., and Brown J.E. Effects of clodronate on serum osteoprotegerin (OPG) in patients with metastatic bone disease. Cancer Treat Rev 32 Suppl. (2006) S40 [Abstract 95]
74. Terpos E., Mihou D., Szydlo R., et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 19 (2005) 1969-1976
75. Lipton A., Hei Y., Coleman R.E., Major P., and Cook R. Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. J Clin Oncol 23 Suppl. (2005) 11s [Abstract 532]
76. Lipton A, Hei Y-J, Coleman RE, Major P, Smith M, Cook RJ. Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer. Poster presented at: the 28th Annual San Antonio breast cancer symposium; December 8-11, 2005. San Antonio (TX). Poster 3015.
77. Fulfaro F., Leto G., Badalamenti G., et al. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17 (2005) 555-559
78. Santini D., Vincenzi B., Hannon R.A., et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15 (2006) 1351-1357
79. Clemons M.J., Dranitsaris G., Ooi W.S., et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24 (2006) 4895-4900
80. Costa L., Demers L.M., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20 (2002) 850-856
81. Tosi P., Zamagni E., Cellini C., et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 76 (2006) 399-404
82. Terpos E., Heath D.J., Rahemtulla A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135 (2006) 688-692
83. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
84. Coleman R.E., Cook R., Major P., et al. Why is zoledronic acid (Z) superior to pamidronate (P) for bone metastases from breast cancer (BC) but equivalent in multiple myeloma (MM)?. Proc Am Soc Clin Oncol 22 Suppl. (2003) 47 [Abstract 187]
85. Terpos E., and Dimopoulos M.-A. Myeloma bone disease: pathophysiology and management. Ann Oncol 16 (2005) 1223-1231
86. Barrett-Lee P., and Murray N. Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI ZICE trial. Bone 38 (2006) S67 Poster 62
87. Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The SWOG trial. Bone 38 Suppl. (2006) S82 [Abstract 101]
88. Paterson A.H. The role of bisphosphonates in early breast cancer. Oncologist 11 Suppl. 1 (2006) 13-19
89. US National Institutes of Health. Clinical trials: randomized study of bone marker-directed schedule versus standard schedule of zoledronic acid in patients with advanced breast cancer metastatic to the bone. Available at: ; 2008 [accessed 21.04.08].
90. UK Clinical Research Network: Portfolio Database. Cost-effective use of BISphosphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule - the BISMARK trial. Available at: ; 2008 [accessed 21.04.08].